Recruiting

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

ClinicalTrials.gov IDNCT06862206

PhaseNot Applicable

Enrollment1000

SponsorAstraZeneca

AgeNo minimum reported

SexALL

I'm interested View official listing

Conditions studied

Chronic Obstructive Pulmonary Disease

About this study

Interventions

Other: benralizumab — non-interventional

Primary outcomes

asthma control questionnaire (Week 8)

Eligibility information

Inclusion criteria -Patients are eligible to be included in the study only if all of the following criteria apply: * Patients must to be 12 years old (inclusive) at the time of signing the informed consent. * Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician. * Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent. * Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures. Exclusion criteria -Patients should not enter the study if any of the following exclusion criteria are fulfilled: * Patients currently participating in any other clinical trial. * Known history of allergy or reaction to any component of the study treatment formulation. * Malignancy of any kind. * Patients with prior or ongoing treatment with benralizumab.

Study locations

Research Site, Anhui, China
Research Site, Anning, China
Research Site, Beijing, China
Research Site, Binzhou, China
Research Site, Changzhou, China
Research Site, Fenyang, China
Research Site, Guangdong, China
Research Site, Guangzhou, China
Research Site, Hangzhou, China
Research Site, Huzhou, China

Showing 10 of 36 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.